Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) insider Robert A. Lenz sold 30,788 shares of the firm’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $11.81, for a total transaction of $363,606.28. Following the sale, the insider now owns 339,205 shares in the company, valued at approximately $4,006,011.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Neumora Therapeutics Trading Up 4.3 %
NMRA stock opened at $12.73 on Friday. Neumora Therapeutics, Inc. has a 12-month low of $8.33 and a 12-month high of $21.00. The business’s 50-day moving average is $11.70 and its 200 day moving average is $11.48.
Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.37). Research analysts expect that Neumora Therapeutics, Inc. will post -1.51 earnings per share for the current year.
Wall Street Analyst Weigh In
View Our Latest Stock Report on Neumora Therapeutics
Institutional Investors Weigh In On Neumora Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Amalgamated Bank acquired a new stake in shares of Neumora Therapeutics in the fourth quarter valued at about $29,000. Quarry LP purchased a new stake in Neumora Therapeutics during the 2nd quarter valued at about $98,000. SkyOak Wealth LLC acquired a new stake in Neumora Therapeutics in the 2nd quarter valued at about $147,000. Principal Financial Group Inc. purchased a new position in Neumora Therapeutics in the 2nd quarter worth approximately $166,000. Finally, SG Americas Securities LLC acquired a new position in shares of Neumora Therapeutics during the 2nd quarter worth approximately $566,000. Institutional investors and hedge funds own 47.65% of the company’s stock.
About Neumora Therapeutics
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Featured Articles
- Five stocks we like better than Neumora Therapeutics
- How to Invest in Insurance Companies: A Guide
- Triple Witching: The Market’s Quarterly Rollercoaster
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- 4 Stocks Set to Benefit from Recent Interest Rate Cuts
- What is the Australian Securities Exchange (ASX)
- Autohome’s Dividend and Buyback Make It a Strong EV Play
Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.